TORONTO, June 2, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, is pleased to announce the
completion of construction and the initiation of operations in its
cultivation, extraction, and analysis facilities in Ibague,
Colombia, where significant
progress has been made towards the commercial registration and
production of medical cannabis products targeting 6 million
potential patients across the country.
Khiron currently owns and operates one of the most sophisticated
medical cannabis cultivation and processing facilities in
Latin America. To date, the
company has:
- Completed development of a state-of-the-art, 14,000 square foot
GMP and ISO 17025 compliant extraction and analysis lab
- Obtained approval from the National Cultivar Registry and
Colombian Institute of Agriculture (ICA) to list a proprietary
selection of strains forming a targeted portfolio to address the
major conditions of pain, epilepsy and sleep disorders. This
approval positions the company to initiate commercial registration,
production and sale of its medical cannabis products across
Colombia
- Begun construction of additional greenhouses to complement
Khiron's initial 80,000 square foot greenhouse
- Established distribution networks to supply high quality
medical cannabis produced in Khiron's main facility, with signed
agreements with 903 pharmacies across Colombia and Khiron Clinics
For more information and most recent images from the Company's
cultivation, extraction analysis facilities, please visit
https://investors.khiron.ca/gallery
About Khiron
Khiron Life Sciences Corp. is positioned to be the dominant
integrated cannabis company in Latin
America. Khiron has core operations in Latin America and is fully licensed in the
country for the cultivation, production, domestic distribution, and
international export of both THC (tetrahydrocannabinol) and CBD
(cannabidiol) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
the first Colombian based medical cannabis company to trade on any
exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at https://investors.khiron.ca/
To be added to the distribution list, please email
khiron@kcsa.com with "Khiron" in the subject line.
CAUTIONARY NOTES
Market and Industry Data
This press release contains market and industry data and
forecasts that were obtained from third-party sources, industry
publications and publicly available information. Third-party
sources generally state that the information contained therein has
been obtained from sources believed to be reliable, but there can
be no assurance as to the accuracy or completeness of included
information. Although management believes it to be reliable, the
Company has not independently verified any of the data from
third-party sources referred to in this press release, or analyzed
or verified the underlying studies or surveys relied upon or
referred to by such sources, or ascertained the underlying economic
assumptions relied upon by such sources.
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Forward-looking statements may be identified by
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Forward-looking
statements herein include, but are not limited to, statements
regarding the anticipated benefits of the distribution agreements,
including online and physical retail consumer exposure, and
potential expansion into other jurisdictions, among others. Readers
are cautioned to not place undue reliance on forward-looking
information. Actual results and developments may differ materially
from those contemplated by these statements. Khiron undertakes no
obligation to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking statements in this
press release are reasonable, such forward-looking statement has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Annual Information Form which is available on Khiron's SEDAR
profile at www.sedar.com. The forward-looking information contained
in this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
United States Disclaimer
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities in
the United States. The securities
have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "U.S. Securities Act") or
any state securities laws and may not be offered or sold within
the United States or to U.S.
Persons (as such term is defined in Regulation S under the U.S.
Securities Act) unless registered under the U.S. Securities Act and
applicable state securities laws or an exemption from such
registration is available.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-completion-of-new-lab-facilities-with-initial-capacity-of-3-tonnes-of-extract-per-year-300860324.html
SOURCE Khiron Life Sciences Corp.